Merck names new heads for North America and China

27 January 2016

Germany’s Merck (MRK: DE) on Wednesday announced two appointments to head its businesses in North America and China in a bid to strengthen its position in the regions.

The comopany named Gary Zieziula president and managing director for its business in North America, and Marc Horn to take the helm of the biopharma business in China.

Mr Zieziula will be responsible for the company’s business in the USA and Canada, with immediate effect. Mr Zieziula joined Merck in 2014 as chief commercial officer in the USA. He succeeds Paris Panayiotopoulos, who accepted a new position outside of Merck at the end of last year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK